Prostate Cancer

The addition of 2 years of androgen-deprivation therapy to radiotherapy after radical prostatectomy improved metastasis-free survival and time to salvage therapy in patients with prostate cancer.

Androgen-deprivation therapy with the addition of apalutamide was effective when used in patients with high-risk biochemically relapsed prostate cancer.

Signs of an overall survival benefit were seen with a regimen of olaparib plus abiraterone acetate and prednisone or prednisolone as a first-line therapy for patients with metastatic castration-resistant prostate cancer, according to updated data from the phase 3 PROpel trial.

Androgen deprivation therapy plus abiraterone acetate and prednisolone resulted in a clinically meaningful overall survival benefit, but this in combination with enzalutamide fell short in patients with metastatic hormone-sensitive prostate cancer.

An updated analysis of the KEYNOTE-365 study of pembrolizumab plus abiraterone showed that patients with chemotherapy-naive metastatic castration-resistant prostate cancer had prostate-specific antigen responses.

Daniel J. George, MD, discusses why he considers using prostate-specific membrane antigen imaging early in treatment of patients with castration-resistant prostate cancer.

During a Targeted Oncology case-based roundtable event, Alan H. Bryce, MD, discussed the case of a patient with high-volume, hormone-naive metastatic prostate cancer.

During a live virtual event, Roby A. Thomas, MD, discussed the tolerability of androgen receptor therapy and personal experiences with treatment of patients with metastatic castration-sensitive prostate cancer. This is the second of 2 articles based on this event.

Olaparib in combination with abiraterone and prednisone, or prednisolone may soon be an FDA-approved treatment for adult patients with metastatic castration-resistant prostate cancer.

Oncologists share some final thoughts on lutetium-PSMA-617 and novel agents to look out for in prostate cancer treatment.

During a live virtual event, Robert Dreicer, MD, MS, discussed the use of cabazitaxel and 177-lutetium-PSMA-617 for patients with metastatic castration-resistant prostate cancer.

The phase 3 KEYNOTE-921 trial did not meet its coprimary end points of overall survival and radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer.

Expert perspectives on the PROfound and TRITON2 studies of olaparib and rucaparib, respectively, in metastatic castration-resistant prostate cancer.

Closing out their discussion on novel treatment approaches in prostate cancer, experts consider future strategies and remaining unmet needs in this setting.

A brief discussion on the importance of germline/somatic BRCA1 and BRCA2 mutations in metastatic CRPC, accompanied by practical advice on genetic testing.

The FDA has approved darolutamide tablets in combination with docetaxel for adult patients with metastatic hormone-sensitive prostate cancer.

High-dose REGN5678 combined with cemiplimab shows preliminary response elicitation in patients with metastatic castration-resistant prostate cancer.

The phase 3 TAVT45CO2 study investigating TAVT-45 in patients with metastatic castrate-sensitive prostate cancer and metastatic castrate-resistant prostate cancer has finished enrollment.

Advanced machine learning and natural language processing approaches were combined to identify patients with non-metastatic castration-resistant prostate cancer from electronic health records data.

Shared insight on the VISION trial, which analyzed 177 Lu-PSMA-617 in previously treated PSMA-positive metastatic castration-resistant prostate cancer.

Moving on to their last patient case, expert panelists review the diagnosis and management of a patient with metastatic castration-resistant prostate cancer.

Alicia Morgans, MD, MPH, presents the case of a 67-year-old man with metastatic castration-resistant prostate cancer.

Experts share their thoughts on sequencing hormonal agents and patient selection for clinical trials.

Ashok Muthukrishnan, MD, MS, addresses the recent FDA approval of lutetium 177Lu vipivotide tetraxetan and looks to the potential of radioimmunotheranostics on the horizon.

A review of recent data from the TheraP trial.

Tanya Dorff, MD, explains safety and efficacy data from the CARD trial.

Michael J. Morris, MD, discusses the results of the VISION trial of 177-lutetium-PSMA-61 in patients with metastatic castration-resistant prostate cancer.

Before closing out their discussion on metastatic CSPC, expert oncologists consider how best to educate patients and address the remaining unmet needs in this setting.

After reviewing data from the ARASENS trial, experts consider the role of the daralutamide-containing triplet regimen in metastatic CSPC.

During a Targeted Oncology case-based roundtable event, Sheela Tejwani, MD, discussed therapy options for a patient with metastatic castration-sensitive prostate cancer.